Gilead SciencesGILD

• Phase ?유전자 변형 세포치료제 투약 환자 장기 추적 관찰 임상진행 중Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
  59%
• Phase 3KITE-753 재발성 대B세포 림프종 비교 임상모집 중Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
  74%
• Phase 3재발·불응성 다발성 골수종 CAR-T 세포치료제 비교 임상모집 중A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
  82%
• Phase 3트로델비 vs 도세탁셀 진행성 비소세포폐암 비교 임상진행 중Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  40%
• Phase 3HIV 고위험군 대상 F/TAF 복합제 예방요법 임상진행 중Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection
  49%
• Phase 3셀라델파르 원발성 담즙성 담관염 치료 유효성 임상진행 중Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
  100%
• Phase ?레나카파비르 HIV(에이즈) 감염 사전 예방 임상모집 중Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
  80%
• Phase 3셀라델파르 간경변 동반 원발성 담즙성 담관염 치료모집 중Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
  100%
• Phase 3HIV 감염 환자 대상 주 1회 경구 복합제 치료 비교 임상진행 중Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
  82%
• Phase 3사시투주맙·펨브롤리주맙 삼중음성유방암 병용 임상모집 중Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
  68%
• Phase 2사시투주맙 고비테칸 전이성 고형암 치료 임상진행 중Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
  59%
• Phase 2테로파비맙·진러비맙·레나카파비르 HIV 병용진행 중A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
  83%

성공 확률은 BERA의 AI 모델(임상 설계·약물 구조·과거 사례 기반)이 계산한 값이에요. 실제 결과와 다를 수 있어요.